Paysign’s (PAYS) Outperform Rating Reaffirmed at Barrington Research

Barrington Research reissued their outperform rating on shares of Paysign (NASDAQ:PAYSFree Report) in a research note published on Monday, Benzinga reports. The brokerage currently has a $7.00 target price on the stock.

Paysign Stock Performance

Shares of PAYS stock remained flat at $3.66 during midday trading on Monday. The company’s stock had a trading volume of 6,464 shares, compared to its average volume of 252,206. Paysign has a one year low of $1.94 and a one year high of $5.59. The stock has a 50-day simple moving average of $4.05 and a 200 day simple moving average of $4.36. The firm has a market capitalization of $194.49 million, a PE ratio of 26.14 and a beta of 0.95.

Insider Buying and Selling at Paysign

In other news, CEO Mark Newcomer sold 50,000 shares of Paysign stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $4.25, for a total value of $212,500.00. Following the sale, the chief executive officer now owns 9,486,886 shares of the company’s stock, valued at $40,319,265.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Paysign news, CEO Mark Newcomer sold 50,000 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $4.25, for a total value of $212,500.00. Following the completion of the sale, the chief executive officer now owns 9,486,886 shares of the company’s stock, valued at approximately $40,319,265.50. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Daniel Spence sold 100,000 shares of the business’s stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $3.60, for a total transaction of $360,000.00. Following the sale, the insider now directly owns 9,090,000 shares in the company, valued at approximately $32,724,000. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 211,000 shares of company stock valued at $800,260. 23.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Paysign

Large investors have recently added to or reduced their stakes in the business. Norden Group LLC boosted its position in Paysign by 38.7% during the first quarter. Norden Group LLC now owns 14,883 shares of the company’s stock worth $54,000 after acquiring an additional 4,151 shares during the last quarter. BNP Paribas Financial Markets increased its position in Paysign by 49.7% during the first quarter. BNP Paribas Financial Markets now owns 39,452 shares of the company’s stock worth $144,000 after purchasing an additional 13,093 shares during the last quarter. Vanguard Group Inc. raised its stake in Paysign by 3.0% during the first quarter. Vanguard Group Inc. now owns 1,649,043 shares of the company’s stock worth $6,035,000 after purchasing an additional 48,489 shares during the period. Herr Investment Group LLC acquired a new position in shares of Paysign in the 1st quarter valued at $179,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Paysign during the 1st quarter valued at $147,000. 25.89% of the stock is owned by institutional investors and hedge funds.

About Paysign

(Get Free Report)

Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.

Recommended Stories

Receive News & Ratings for Paysign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paysign and related companies with MarketBeat.com's FREE daily email newsletter.